Ascorbic acid 2-glucoside priming enhances mesenchymal stem cell-mediated peripheral nerve regeneration through MAPK/ERK-NTF-3 signaling
Background Peripheral nerve injury (PNI) often results in incomplete nerve regeneration and persistent functional deficits. While mesenchymal stem cell (MSC) therapies offer promise, their clinical translation is hindered by a loss of efficacy after in vitro expansioneclarations and progressive cellular heterogeneity. Priming strategies present a viable solution to enhance regenerative capacity and therapeutic consistency. Furthermore, establishing optimal transplantation dosages and ensuring clinical safety remains critical for successful application. Methods To enhance the therapeutic potential of human Wharton’s jelly-derived MSCs (hWJ-MSCs) without genetic modification, cultures were primed with an optimized concentration of ascorbic acid 2-glucoside (AA2G). In vitro enhancements were evaluated via proliferation, transwell migration, colony-forming unit-fibroblast (CFU-F), scratch, and neurite outgrowth assays, alongside comprehensive molecular characterizations (Western blotting, qRT-PCR, IF staining, ELISA, and mRNA-seq). In vivo efficacy was assessed using a rat sciatic nerve injury model across two studies: (1) a comparison of Naïve MSCs and AA2G-MSCs, and (2) an evaluation of the dose-dependent effects of AA2G-MSCs. Cells were administered during autologous nerve grafting. Functional and structural recovery was evaluated 16 weeks post-transplantation using gait cycle analysis, joint contracture angle, motor nerve conduction velocity (MNCV), isometric tetanic force testing, and comprehensive histomorphometric analyses of muscle and nerve tissues (H&E, MT, TB staining, and TEM). Results AA2G-MSCs exhibited enhanced proliferation, migration, and self-renewal. Transcriptomic and molecular analyses demonstrated that AA2G priming upregulated the neurotrophic factor NTF-3 by activating the MAPK/ERK signaling pathway. In vivo, AA2G-MSC transplantation significantly improved motor recovery and increased muscle mass. Histological evaluations confirmed superior peripheral nerve regeneration in the AA2G-MSC group, characterized by robust axonal remyelination, expanded muscle fiber cross-sectional areas (CSA), and reduced muscle fibrosis. Additionally, the comparative dose analysis successfully established the optimal transplantation dose for maximizing therapeutic outcomes. Conclusion AA2G priming effectively promotes peripheral nerve regeneration by enhancing the functional and secretory capacities of hWJ-MSCs. This therapeutic effect is associated with activation of the MAPK/ERK–NTF-3 signaling axis. By identifying an effective transplantation dose and demonstrating robust in vivo efficacy, this study supports AA2G priming as a non-genetic strategy with strong translational potential for advancing MSC-based therapies for PNI.
Authors
- Chae‐Min Ryu (ORCID: https://orcid.org/0000-0001-5326-9255)
- Min-Young Jo (ORCID: https://orcid.org/0009-0008-8069-7624)
- Jae Kwang Kim (ORCID: https://orcid.org/0000-0001-5104-4634)
- Won Sun Lee
Institutions
- Asan Medical Center (KR)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-18
- DOI
- https://doi.org/10.21203/rs.3.rs-11587438/v1
- Primary Topic
- Nerve injury and regeneration
- Type
- preprint